You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Novel A2A Adenosine Agonists in Vascular Protection

    SBC: ADENOSINE THERAPEUTICS, LLC            Topic: N/A

    DESCRIPTION (provided by applicant): This is a phase II SBIR proposal to develop a new drug eluting stent to prevent restenosis. It is a 3-way collaboration between Adenosine Therapeutics, LLC, Setagon, Inc., and the University of Virginia. The work described here will be done at Adenosine Therapeutics (compound synthesis and pharmacokinetics) and the University of Virginia (Stent studies in pigs) ...

    STTR Phase II 2004 Department of Health and Human ServicesNational Institutes of Health
  2. Incorporating Bone Minerals into Orthopaedic Surfaces

    SBC: ADVANCED SURFACES AND PROCESSES, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Submerged Electro-Spark Deposition (SESD, US patent pending), developed at Advanced Surfaces And Processes, Inc., is a surface modification technique. Any conductive surface can be modified with regards to surface texture and chemical composition. The objective of the present proposal is to use SESD to incorporate appreciable amounts of bone mineral elements, i ...

    STTR Phase I 2004 Department of Health and Human ServicesNational Institutes of Health
  3. Recombinant Lactoferrin and Necrotizing Enterocolitis

    SBC: AGENNIX, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): This feasibility study is based on our hypothesis that recombinant human lactoferrin [rhLF] can prevent or reduce severity of necrotizing enterocolitis [NEC]. NEC is mainly a disease of very low birth weight [VLBW] human infants. It is a leading cause of morbidity and mortality in neonatal intensive care units, with incidence of approximately 10 percent in VLBW ...

    STTR Phase I 2004 Department of Health and Human ServicesNational Institutes of Health
  4. T7 RNA polymerase engineering and RNA amplification

    SBC: AMBION DIAGNOSTICS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Microarrays are powerful tools that can impact new diagnostic procedures and expedite the drug development process. A significant but largely unrealized application is gene expression analysis from RNAlimited samples, such as blood, needle biopsies, laser capture microdissection (LCM) samples, and even single cells. The most widely used T7 RNA polymerase-based ...

    STTR Phase I 2004 Department of Health and Human ServicesNational Institutes of Health
  5. Scanning Miniature Imaging Probes For Optical Biopsy

    SBC: ARCHER OPTX, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): This Phase I proposal is a collaborative, multi-disciplinary effort involving researchers from TPL, Inc. (Albuquerque, New Mexico) and the Department of Bioengineering at the University of Washington. Our objective is to explore a new generation of miniature optical imaging probes for high-resolution intraluminal imaging of neoplasia at early stages. Developm ...

    STTR Phase I 2004 Department of Health and Human ServicesNational Institutes of Health
  6. Development of a Peptide Microchip System

    SBC: ATACTIC TECHNOLOGIES, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): The purpose of this proposal is to develop a protein assay technology that will parallel the newly developing oligonucleotide microarray techniques. We will develop a peptide system capable of performing high throughput real time measurements in parallel on a microfluidic chip. We will develop the chemistry to prepare these chips in Phase I and develop the s ...

    STTR Phase II 2004 Department of Health and Human ServicesNational Institutes of Health
  7. Morpholino Antisense Drugs for Hepatitis C Virus

    SBC: Avi Biopharma, Inc.            Topic: N/A

    DESCRIPTION (provided by applicant): Hepatitis C Virus (HCV) causes a persistent infection in most humans exposed to the virus. HCV infection in time can lead to cirrhosis and hepatocellular carcinoma. Although the annual number of newly infected patients has dropped significantly over the past decade, about 4 million people are currently persistently infected in the USA. There is presently no un ...

    STTR Phase I 2004 Department of Health and Human ServicesNational Institutes of Health
  8. Novel Skin Barrier to Prevent and Treat Poison Ivy

    SBC: Biomedical Development Corporation            Topic: N/A

    DESCRIPTION (provided by applicant): Poison ivy/oak dermatitis (also known as Toxicodendron dermatitis) is the most common allergic contact dermatitis in the United States, affecting millions of Americans every year. The prevalence of poison ivy and oak sensitivity in the general adult population ranges from 50 to 70%, and the sensitivity and severity of skin inflammation can range from minor i ...

    STTR Phase I 2004 Department of Health and Human ServicesNational Institutes of Health
  9. Feasibility Evaluation of a Prosthetic Venous Value

    SBC: BIOMEDICAL RESEARCH ASSOCIATES, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): The goal of this Phase I STTR proposal is to demonstrate the feasibility of a novel prosthetic venous valve design concept. One of the ultimate goals in vascular surgery is to develop a successful prosthetic venous valve to replace defective valves in patients with chronic venous insufficiency (CVI). More than 8 million Americans suffer from the debilitating c ...

    STTR Phase I 2004 Department of Health and Human ServicesNational Institutes of Health
  10. Pretest Probability Assessment for Pulmonary Embolism

    SBC: BREATHQUANT MEDICAL SYSTEMS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Pretest probability assessment (PTP) plays a pivotal role in the evaluation of pulmonary embolism (PE) in the emergency department (ED) and accurate PTP assessment can modify defensive test-ordering behavior by physicians. However, current methods of PTP assessment produce broad categories of risk that tend to over fit individual patients and seldom obviate tes ...

    STTR Phase II 2004 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government